Future therapies may involve combining strategies targeting the ECM with existing lipid-lowering therapies (e.g., statins or PCSK9 inhibitors) or anti-inflammatory drugs to provide a more comprehensive approach to treating atherosclerosis and improving cardiovascular outcomes. This evidence concerns the gene PCSK9 and atherosclerosis.